Rhenman & Partners Asset Management AB trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 13.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,000 shares of the medical research company’s stock after […]